World's Best Scientists 2026 revealed!
Beatriz Grinsztejn

Beatriz Grinsztejn

Award Badge
Microbiology
Brazil
2026

D-Index & Metrics

Microbiology

D-Index
76
Citations
31951
World Ranking
1384
National Ranking
7

Beatriz Grinsztejn publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Beatriz Grinsztejn sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 492 publications — 95th percentile

95% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Beatriz Grinsztejn D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Beatriz Grinsztejn sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 76 D-Index — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Microbiology in Brazil Leader Award

Overview

Beatriz Grinsztejn is affiliated with the Oswaldo Cruz Foundation in Brazil. Their research primarily spans the field of Medicine, with a particular focus on Infectious Diseases, Epidemiology, and Virology. Additional areas of interest include Sociology and Political Science as well as Emergency Medicine.

Their work addresses a variety of major topics including HIV/AIDS Research and Interventions, HIV Research and Treatment, and HIV, Drug Use, Sexual Risk. Other key topics within their scientific scope are HIV/AIDS drug development and treatment, SARS-CoV-2 and COVID-19 Research, issues related to sex work, and HIV-related health complications and treatments.

Grinsztejn has contributed to scholarly literature in numerous journals and platforms. Frequent publication venues include:

  • UNC Libraries
  • Journal of the International AIDS Society
  • The Brazilian Journal of Infectious Diseases
  • AIDS and Behavior
  • The Lancet Regional Health - Americas

The scientist has collaborated regularly with several researchers over the years. Frequent co-authors include:

  • Valdiléa G. Veloso
  • Sandra Wagner Cardoso
  • Thiago S. Torres
  • Brenda Hoagland
  • Emília M. Jalil

Selected recent papers by Grinsztejn feature contributions to prominent journals and cover topics related to infectious diseases and HIV research. Notable publications include:

  • "Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19," 2021, New England Journal of Medicine
  • "Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women," 2021, New England Journal of Medicine
  • "Mpox in people with advanced HIV infection: a global case series," 2023, The Lancet
  • "Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S," 2022, New England Journal of Medicine
  • "A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19," 2021, Journal of Clinical Investigation

Best Publications

  • Prevention of HIV-1 Infection with Early Antiretroviral Therapy

    Myron S. Cohen;Ying Q. Chen;Marybeth McCauley;Theresa Gamble

  • Antiretroviral Therapy for the Prevention of HIV-1 Transmission

    Myron S. Cohen;Ying Q. Chen;Marybeth McCauley;Theresa Gamble

  • Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

    Raphael J Landovitz;Deborah Donnell;Meredith E Clement;Brett Hanscom

  • Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

    Beatriz Grinsztejn;Bach Yen Nguyen;Christine Katlama;Jose M. Gatell

  • Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial

    Beatriz Grinsztejn;Mina C. Hosseinipour;Heather J. Ribaudo;Susan Swindells

  • Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial

    Jean Michel Molina;Pedro Cahn;Beatriz Grinsztejn;Adriano Lazzarin

  • Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

    Pedro Cahn;Anton L Pozniak;Horacio Mingrone;Andrey Shuldyakov

  • What drives the US and Peruvian HIV epidemics in men who have sex with men (MSM)

    Steven M. Goodreau;Nicole Bohme Carnegie;Eric Vittinghoff;Javier R. Lama

  • Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis

    Nathan Ford;Zara Shubber;Graeme Meintjes;Beatriz Grinsztejn

  • Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

    Margaret Johnson;Beatriz Grinsztejn;Claudia Rodriguez;Jeffrey Coco

  • 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.

    Margaret Johnson;Beatriz Grinsztejn;Claudia Rodriguez;Jeffrey Coco

  • Three Postpartum Antiretroviral Regimens to Prevent Intrapartum HIV Infection

    Karin Nielsen-Saines;D. Heather Watts;Valdilea G. Veloso;Yvonne J. Bryson

  • Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.

    Christine Katlama;Roberto Esposito;Jose M Gatell;Jean-Christophe Goffard

  • Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study

    Beatriz Grinsztejn;Brenda Hoagland;Ronaldo I Moreira;Esper G Kallas

  • The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.

    F. Van Leth;S. Andrews;B. Grinsztejn;E. Wilkins

  • Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials

    Calvin J. Cohen;Jean-Michel Molina;Pedro Cahn;Bonaventura Clotet

  • Unveiling of HIV dynamics among transgender women: a respondent-driven sampling study in Rio de Janeiro, Brazil

    Beatriz Grinsztejn;Emilia M Jalil;Laylla Monteiro;Luciane Velasque

  • Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors.

    David R Bakal;Lara E Coelho;Paula M Luz;Jesse L Clark

  • Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in HIV-1–Infected Women

    Erna Milunka Kojic;Minhee Kang;Michelle S. Cespedes;Triin Umbleja

  • TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis

    Nathan Ford;Alberto Matteelli;Alberto Matteelli;Zara Shubber;Sabine Hermans;Sabine Hermans

  • The future role of CD4 cell count for monitoring antiretroviral therapy

    Nathan Ford;Nathan Ford;Graeme Meintjes;Anton Pozniak;Helen Bygrave

  • Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

    Raphael J. Landovitz;Sue Li;Beatriz Grinsztejn;Halima Dawood

  • Changing Mortality Profile among HIV-Infected Patients in Rio de Janeiro, Brazil: Shifting from AIDS to Non-AIDS Related Conditions in the HAART Era

    Beatriz Grinsztejn;Paula M. Luz;Antonio G. Pacheco;Desiree V. G. Santos

  • HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel.

    Jeanne M. Marrazzo;Carlos del Rio;David R. Holtgrave;Myron S. Cohen

  • Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.

    Thomas B. Campbell;Laura M. Smeaton;N. Kumarasamy;Timothy Flanigan

Frequent Co-Authors

Paula M. Luz
Paula M. Luz Oswaldo Cruz Foundation
Pedro Cahn
Pedro Cahn University of Buenos Aires
Kenneth H. Mayer
Kenneth H. Mayer Harvard Medical School
Myron S. Cohen
Myron S. Cohen University of North Carolina at Chapel Hill
Susan H. Eshleman
Susan H. Eshleman Johns Hopkins University School of Medicine
Eduardo Gotuzzo
Eduardo Gotuzzo Instituto de Medicina Tropical Alexander von Humboldt
Judith S. Currier
Judith S. Currier University of California, Los Angeles
Joseph J. Eron
Joseph J. Eron University of North Carolina at Chapel Hill
Joseph Makhema
Joseph Makhema Harvard University
Jean-Michel Molina
Jean-Michel Molina Université Paris Cité

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Microbiology opens doors to diverse career opportunities, many of which can be enhanced through related online degrees. For those with a complex background, it’s encouraging to note that the best degree for felons options include programs that offer flexibility and a fresh start in scientific and healthcare fields.

Healthcare-related pathways often align well with microbiology studies. For example, becoming a functional medicine nurse practitioner can be a fulfilling career choice, blending microbiological science with holistic patient care. This role requires specialized knowledge that can be pursued through online education and certification programs.

Alternatively, careers in medical coding and health information are also accessible to microbiology graduates. Understanding the cpc salary landscape demonstrates that certified professional coders have promising earning potential and job stability, making it a compelling option for those interested in healthcare administration.

Similarly, learning about health information management salary entry-level roles highlights opportunities in managing patient data and healthcare systems, careers that complement microbiological knowledge with information technology and management skills.

Best Scientists Citing Beatriz Grinsztejn

Trending Scientists